Sanofi expands its Hyderabad center to 4,500 employees, boosting R&D and innovation in India.

Japan's panel backs first iPS cell therapies for Parkinson’s and heart disease, pending minister approval.

Fractal AI's Vaidya 2.0, a healthcare AI model, scored 50.1 on a key benchmark, becoming the first to exceed 50, and integrates with India’s digital health systems for real-world medical use.

Gazyva showed strong results in treating primary membranous nephropathy, a kidney disease, potentially becoming the first approved therapy for it.

Gilead Sciences beat earnings estimates, raised 2026 guidance, and saw stock momentum despite long-term growth questions.

A phase 2b trial shows duvakitug, from Sanofi and Teva, offers lasting relief for ulcerative colitis and Crohn’s disease patients.

Nuclera and leadXpro partner to accelerate drug discovery for tough membrane proteins using AI, cell-free synthesis, and cryo-EM.

Nanovibronix trails peers in key metrics despite better earnings and lower P/E, with higher volatility and weaker growth outlook.

A brain training game targeting attention and speed may cut dementia risk by 25% in adults over 65.

AbbVie beat earnings expectations in Q4 2025, raised 2026 guidance, and saw increased investor interest.